Navigation Links
VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year'


BEDFORD, Mass., Dec. 1 /PRNewswire/ -- The Radiologic Society of North America (RSNA) honored Ralph Weissleder, MD, PhD, with its "Outstanding Researcher of The Year" Award, recognition afforded annually to one scientist who has made original significant contributions to the field of radiology throughout a career of research. Dr. Weissleder is Professor at Harvard Medical School, as well as Director of both the Center for Systems Biology and the Center for Molecular Imaging Research at Massachusetts General Hospital (MGH).

"The RSNA 'Outstanding Researcher of the Year' award is an important acknowledgement of Dr. Weissleder's vision for molecular imaging as an integral component in the future of clinical medicine," said Kirtland Poss, CEO of VisEn Medical. "Dr. Weissleder's contributions have already benefited basic research and pharmaceutical development across numerous disease states, and these are increasingly advancing the era of personalized- and improved-medicine."

According to the RSNA, each "Outstanding Researcher of the Year" honoree has demonstrated a long-term commitment to radiologic research, including service as a principal investigator on peer-reviewed, nationally funded research programs, mentoring a new generation of research physicians, and leading significant scientific discoveries.

Dr. Weissleder has published over 500 peer-reviewed articles and is a founding member and past President of the Society for Molecular Imaging Research. He is the recipient of numerous scientific awards including the Allyn Taylor Prize in International Medicine, an SMI Lifetime Achievement Award and the Millennium Innovator in Medicine award.

Dr. Weissleder is also known for his significant contributions to molecular imaging research. Most of his work has been aimed at cancer, atherosclerosis and inflammatory diseases and has led to new approaches in the management of these diseases.

Dr. Weissleder is a co-founder of VisEn Medical, which has further developed and commercialized some of the leading fluorescence molecular imaging technologies originating out of Dr. Weissleder's lab at MGH, including "FMT" or fluorescent molecular tomography, as well as a portfolio of fluorescence in vivo imaging agents. The VisEn FMT 2500(TM) quantitative tomography system provides 3D quantification of disease biologies in vivo and is used by leading research institutions and pharma companies worldwide both in research and in drug development. In addition, VisEn develops and markets a broad range of fluorescent in vivo imaging agents enabling the quantification and measurement of key disease-associated biomarkers and therapeutic responses in vivo. These agents are used preclinically today, and along with the Fox Chase Cancer Center, VisEn's first "smart" fluorescence activatable agent is being planned for clinical trials in late 2009 to enable physicians to identify and characterize early stage disease in pancreatic and ovarian cancer patients.

Information on Dr. Weissleder and his work at the MGH can be found on: and

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMT) Imaging Systems provide the industry's most robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific preclinical and clinical research areas.

Additional information can be found at

SOURCE VisEn Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
2. VisEn Medical Raises $5.0 Million in Expanded Series B Financing
3. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
4. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
5. Statement by Steve Case, Co-Founder, AOL and Chairman of Accelerate Brain Cancer Cure ( on News of Senator Ted Kennedys Brain Cancer Diagnosis
6. The Chopra Center Co-founders Bring Mind-Body Healing to New York City
7. The Chopra Center Co-founders Will Teach a Beginning Course in Meditation and Mind-body Healing This August in Chicago
8. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
9. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
10. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
11. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: